Skip to main content
Fig. 6 | Arthritis Research & Therapy

Fig. 6

From: Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis

Fig. 6

MCP-1 production in SFMC cultures treated with pembrolizumab combined with different DMARDs. A MCP-1 production in SFMCs cultured for 48 h untreated (UT) or treated with pembrolizumab (Pembro), pembrolizumab + adalimumab (Ada), pembrolizumab + tocilizumab (Toci) (n = 10, 2 RA patients, 4 PsA patients, and 4 SpA patients). A MCP-1 production in SFMCs cultured for 48 h untreated (UT) or treated with DMSO, pembrolizumab (Pembro), pembrolizumab + tofacitinib (Tofa), or pembrolizumab + baricitinib (Bari) (n = 7, 3 PsA patients and 4 SpA patients). C, D Data were normalized to untreated cultures and expressed as ratios. Data is expressed as median with interquartile range.. Log-transformed ratios were analyzed with the paired Student’s t-test. *P-value < 0.05, **P-value < 0.01, ***P-value < 0.001. DMSO, dimethyl sulfoxide; Pembro, pembrolizumab; Ada, adalimumab; Toci, tocilizumab; Tofa, tofacitinib; Bari, baricitinib

Back to article page